Effectiveness and Tolerability of Ivabradine with or Without Concomitant Beta-Blocker Therapy in Patients with Chronic Stable Angina in Routine Clinical Practice.

Treatment of Stable Angina with a New Fixed-Dose Combination of Ivabradine and Metoprolol: Effectiveness and Tolerability in Routine Clinical Practice. Cardiol Ther (2017) 0.75

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J (2012) 16.00

2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet (2010) 8.17

Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med (2014) 5.41

Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 5.03

2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol (2012) 4.77

Resting heart rate in cardiovascular disease. J Am Coll Cardiol (2007) 4.14

Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J (1987) 4.12

β-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease. J Am Coll Cardiol (2014) 3.55

Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet (2008) 3.36

Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med (2014) 2.94

Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet (2010) 2.80

Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J (2005) 2.78

Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J (2009) 2.21

Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J (2009) 1.91

Vascular pathophysiology in response to increased heart rate. J Am Coll Cardiol (2010) 1.88

Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs (2004) 1.85

A review of health utilities using the EQ-5D in studies of cardiovascular disease. Health Qual Life Outcomes (2010) 1.83

Efficacy of ivabradine in combination with Beta-blocker versus uptitration of Beta-blocker in patients with stable angina. Cardiovasc Drugs Ther (2011) 1.56

Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. Br J Pharmacol (2008) 1.23

Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs (2007) 1.18

Heart rate reduction in cardiovascular disease and therapy. Clin Res Cardiol (2010) 1.08

Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study. Clin Res Cardiol (2012) 1.02

Prognosis of patients with stable coronary artery disease (from the CORONOR study). Am J Cardiol (2014) 0.90

Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. PLoS One (2012) 0.89

Inadequate control of heart rate in patients with stable angina: results from the European heart survey. Postgrad Med J (2010) 0.87

β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes (2014) 0.86

Pleiotropic, heart rate-independent cardioprotection by ivabradine. Br J Pharmacol (2015) 0.84

Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice. Adv Ther (2014) 0.82

Resting heart rate is an independent predictor of all-cause mortality in the middle aged general population. Clin Res Cardiol (2016) 0.81

Treatment of stable angina pectoris by ivabradine in every day practice: the REDUCTION study. Am Heart J (2009) 0.81

Ivabradine in combination with beta-blocker therapy for the treatment of stable angina pectoris in every day clinical practice. Clin Res Cardiol (2010) 0.78

Ivabradine: Cardioprotection By and Beyond Heart Rate Reduction. Drugs (2016) 0.77

Ivabradine in chronic stable angina: Effects by and beyond heart rate reduction. Int J Cardiol (2016) 0.77

Treatment of Stable Angina with a New Fixed-Dose Combination of Ivabradine and Metoprolol: Effectiveness and Tolerability in Routine Clinical Practice. Cardiol Ther (2017) 0.75